Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines

Monsonégo, Joseph; Zerat, Laurent; Syrjänen, Karí; Zerat, Jean Claude; Smith, Jennifer S.; Halfon, Philippe

doi:10.1016/j.vaccine.2012.06.013

Cited by 42 publications

(37 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding that HPV16 was the most prevalent single HPV genotype in the general population and was 2-3 times more prevalent than HPV18 is consistent with that of Wheeler et al [21] HPV16 was also found to be the most prevalent among those genotypes classified as oncogenic by Hariri et al [22] and Monsonego et al [23] in women aged ≥25 years.…”

Section: Discussionsupporting

confidence: 91%

“…These results are similar to those of Wheeler et al; the highest prevalence of any carcinogenic type in women ≥25 years was found in ages 25-29 years (21.8%) and the lowest prevalence in women N50 years (6.9%) [21]. Further similarity was seen with the data of Hariri et al [22] in the U.S. and Monsonego et al [23] in France. The results presented here are also similar to what was reported in a meta-analysis of ≈ 1 million women worldwide with negative cytology in which the highest prevalence of HPV infection occurred in the youngest women, decreasing progressively with age and then showing a slight increase in women aged ≥55 years [24].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Monsonégo

Cox

Behrens

et al. 2015

Gynecologic Oncology

Self Cite

133

135

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Monsonégo

Cox

Behrens

et al. 2015

Gynecologic Oncology

Self Cite

133

135

View full text Add to dashboard Cite

show abstract

“…However, our results are in contrast with some other international reviews [23] and with the HPV prevalence observed in several European countries like Denmark [24] or the Netherlands [25]. They are also inconsistent with the HPV prevalence seen in a recent French study [26]. The discrepancy observed between these various studies is well known [27] and is probably linked to variability in recruitment criteria.…”

Section: Age Related Prevalencecontrasting

confidence: 99%

Type-Specific Human Papillomavirus Testing for the Follow-up of Women with a Typical Squamous Cells of Undetermined Significance (ASCUS) Pap Smears

Gonfrier¹,

Delotte²,

Bongain³

et al. 2015

Arch Can Res

View full text Add to dashboard Cite

Background: The aim of our study was to assess the prevalence of Human papillomavirus (HPV) genotypes amongst women diagnosed with Atypical Squamous Cells of Undetermined Significance (ASC-US) Pap smears in southern France and to determine whether the systematic application of HPV genotyping in this patient population could improve the ability to identify women with a higher or lower risk of progression to cervical cancer or CIN2 or 3. The ultimate goal is to limit the number of colposcopy performed unnecessarily in women with ASC-US cytology.

show abstract

“…For instance, in French women under 25 years of age undergoing routine gynaecological examinations, Monsonego et al found a prevalence of 9.3%, although these women were not selected through the filter of normal cytological findings [46]. The lower prevalence observed by Monsonego et al could be explained by the fact that the mean age of the French women was probably higher than that of the women in our sample [46]. …”

Section: Discussionmentioning

confidence: 71%

Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?

et al. 2013

View full text Add to dashboard Cite

BackgroundHuman Papillomavirus (HPV) is the most common sexually transmitted infection. In Italy, HPV vaccination is now offered free of charge to 12-year-old females. However, some regional health authorities have extended free vaccination to other age-groups, especially to girls under 18 years of age. We conducted a multicentre epidemiological study to ascertain the prevalence of different genotypes of HPV in young Italian women with normal cytology, with the aim of evaluating the possibility of extending vaccination to older females.MethodsThe study was performed in 2010. Women aged 16–26 years with normal cytology were studied. Cervical samples were analyzed to identify the presence of HPV by PCR amplification of a segment of ORF L1 (450 bp). All positive HPV-DNA samples underwent viral genotype analysis by means of a restriction fragment length polymorphism assay.ResultsPositivity for at least one HPV genotype was found in 18.2% of the 566 women recruited: 48.1% in the 16–17 age-class, 15.4 in the 18–20 age-class, 21.9% in the 21–23 age-class, and 15.5% in the 24–26 age-class; 10.1% of women were infected by at least one high-risk HPV genotype. HPV-16 was the most prevalent genotype. Only 4 (0.7%), 4 (0.7%) and 3 (0.5%) women were infected by HPV-18, HPV-6 and HPV-11, respectively. Of the HPV-DNA-positive women, 64.1% presented only one viral genotype, while 24.3% had multiple infections. The HPV genotypes most often involved in multiple infections were high-risk. A high prevalence was noted in the first years of sexual activity (48.1% of HPV-DNA-positive women aged 16–17 years); HPV prevalence subsequently declined and stabilized.The estimate of cumulative proportions of young women free from any HPV infection at each age was evaluated; 93.3% and 97.1% of 26 year-old women proved free from HPV-16 and/or HPV-18 and from HPV-6 and/or HPV-11, respectively.ConclusionsOur findings confirm the crucial importance of conducting studies on women without cytological damage, in order to optimise and up-date preventive interventions against HPV infection, and suggest that vaccinating 26-year-old females at the time of their first pap-test is to be recommend, though this issue should be further explored.

show abstract

Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines

Cited by 42 publications

References 38 publications

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Type-Specific Human Papillomavirus Testing for the Follow-up of Women with a Typical Squamous Cells of Undetermined Significance (ASCUS) Pap Smears

Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?

Contact Info

Product

Resources

About